Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
attIL12-TIL Cell Therapy in Advanced/Metastatic Sarcoma
NCT06474676Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2025
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 1, open-label trial of attIL12-TIL in soft tissue sarcoma (STS), bone sarcoma and Liposarcoma (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and adverse events at 1 year, Maximum Tolerated Dose and Recommended Phase 2 Dose and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
attIL12-TIL
03
Conditions
soft tissue sarcoma (STS)bone sarcomaLiposarcoma
Beyond the preview
Go deeper on NCT06474676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06474676.